The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an ...

In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

Discover a study that assessed the risk of hospitalisation for serious infections based on different categories of systemic ...

Korea: A recent retrospective cohort study published in the Journal of the American Academy of Dermatology explored the link ...

A new cohort study published in Journal of American Medical Association suggests that biologics targeting IL-12, IL-23, and ...

Patients with generalized pustular psoriasis continued to experience frequent flares that were often uncontrolled by ...

The following is a summary of “’Ugh…how do you catch that?" - A qualitative study of the impact of psoriasis on social ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

For more than 11,000 older adults started on systemic treatment for psoriasis or psoriatic arthritis, rates of serious infection per 100 person-years were 2.7 with methotrexate; 2.5 with other ...

That risk increased to 97% higher for people using systemic treatment. Cirrhosis and MASLD had the strongest associations with psoriasis. These findings are consistent with those from a 2022 study ...